Confluent Medical Technologies is set to invest over $50 million in ATI’s Nitinol melt and materials conversion infrastructure, significantly increasing ATI’s medical Nitinol melt capacity. Confluent will become ATI’s fulfillment partner, offering value-add services and order fulfillment for ATI’s medical Nitinol mill product. The investment addresses the growing demand in neurovascular, electrophysiology, structural heart, peripheral vascular, and orthopedic device markets. The expansion at ATI’s Millersburg, Oregon facility is expected to be operational in 2027, ensuring a reliable Nitinol supply chain.
Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more than $50 million over the next several years in ATI’s Nitinol melt and materials conversion infrastructure. With this significant investment, which will more than triple ATI’s melt capacity for medical Nitinol, Confluent will become ATI’s fulfillment partner and provide a suite of value-add services and order-fulfillment for ATI medical Nitinol mill product.
“The growth in Neurovascular, Electrophysiology, Structural Heart, Peripheral Vascular, and Orthopedic device markets is driving an 18% growth rate (CAGR) in Nitinol demand. Given the substantial equipment and infrastructural cost needed to increase supply chain capacity, the industry has struggled to support this growth,” stated Dean Schauer, CEO and President of Confluent. “Our investment in this critical infrastructure will provide the necessary mid-term and long-term melt and conversion capacity necessary to meet and support Nitinol material demand. As the most trusted supply partner for our OEM customers, Confluent is pleased to be making this investment in creating a reliable supply chain so that OEMs can continue providing life-saving devices in these specialized markets.”
“ATI is honored to partner with Confluent in producing what is literally a life-saving material,” said Rob Foster, President of ATI’s Specialty Alloys & Components business. “We appreciate the value Confluent places on our expertise and capabilities as the industry leader in Nitinol production. Confluent’s investment in ATI’s growth will ensure the stable supply of Nitinol the industry needs for growth.” The expansion at ATI’s Millersburg, Oregon facility is expected to come online in 2027.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
With these expanded capabilities and capacity investments, Confluent will continue to provide customers with the most reliable supply chain delivering the broadest level of Medical Nitinol services in mill products, hollows, tubes, wires, and components.
Source:Bio space